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ABSTRACT 
Background: Current practices emphasize a multimodal approach to perioperative 
analgesia due to higher efficacy and decreased opioid usage. Analgesia for 
pancreas transplant (PT) has traditionally been managed with intravenous (IV) 
opioids, and reports of transversus abdominis plane (TAP) blocks are limited in this 
population.  
 
Methods: Three interventions were compared in adult PT patients, including IV 
opioids, TAP catheter, and TAP block with liposomal bupivacaine. Time to return of 
intestinal function and oral diet, postoperative pain scores, opioid usage, and length 
of stay were recorded.  
 
Results: Study included 197 PT patients: 62 (32%) standard care, 90 (45%) TAP 
catheters with continuous 0.2% ropivacaine, and 45 (23%) single liposomal 
bupivacaine TAP block. Pain scores were lowest for the IV opioids group (P < .001). 
The liposomal bupivacaine group had lower pain scores on postoperative (POD) day 
1-5 than the TAP catheter group. Opioid use during POD 1-5 was lower for both TAP
block groups (P = .03). Time to bowel function was faster for the TAP block groups 
(P < .05).  
 
Conclusions: Compared with IV opioid analgesia, TAP block interventions were 
associated with lower overall use of opioids and a faster time to intestinal function 
following pancreas transplant.  
 
KEYWORDS: TAP block, regional analgesia, multimodal, ropivacaine, postoperative 
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INTRODUCTION 
Abdominal organ transplants may cause a high level of postoperative pain, as the 
surgery involves a long incision through the abdominal wall. Uncontrolled 
postoperative pain may lead to complications causing increased morbidity and 
longer hospital stays. Recent analgesia practices emphasize a multimodal approach 
by targeting multiple areas in the pain pathway thus decreasing the use of opioids.1 
During abdominal procedures, a transversus abdominis plane (TAP) block may be 
used to help control the source of incisional pain.  
 
The TAP block blunts neural afferents from T6 to L1 that supply the anterior 
abdominal wall, as local anesthetic is injected just deep to the fascial plane between 
the transversus abdominis and internal oblique muscles. The first TAP block 
technique (described by Rafi et al in 2001)2 targeted the triangle of Petit bordered by 
the latissimus dorsi, external oblique, and iliac crest. Since then, ultrasound has 
been used to continuously visualize the needle tip and anatomical landmarks.2,3 The 
TAP block has been shown to be an effective non-opioid method of pain control in 
abdominal surgeries,4-9 leading to reduced postoperative opioid consumption and 
improved pain scores.10 Such benefits have been documented specifically for renal 
transplant recipients.11-14  
 
In December 2015, the United States Food & Drug Administration (FDA) approved 
liposomal bupivacaine for “local surgical infiltration”, thus expanding its use to TAP 
blocks. Bupivacaine has a long terminal half-life of 3.5 hours due to extensive protein 
binding. In a liposomal formulation, the internalized bupivacaine can be released in a 
delayed way as the multivesicular liposomes are biodegraded.15 Patients given 
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liposomal bupivacaine TAP blocks in abdominal procedures have shown decreased 
length of stay (LOS) and opioid use, and improved pain scores as compared to only 
intravenous (IV) pain management.16,17 Hutchins’ study comparing bilateral subcostal 
TAP blocks with single administration of bupivacaine versus liposomal bupivacaine 
demonstrated decreased total opioid requirement for the first 72 hours following a 
robot assisted hysterectomy.18 Another study compared liposomal bupivacaine to 
continuous epidural analgesia with plain bupivacaine and IV opioid management, 
finding similar postoperative pain scores and opioid use between the continuous 
epidural group and the liposomal bupivacaine group.19  
 
Pancreas transplantation has the potential to render diabetic recipients euglycemic 
and is most commonly performed either as a simultaneous pancreas and kidney 
transplant (SPK) or as a pancreas after kidney (PAK) transplant. Less frequently, 
pancreas transplant alone (PTA) may be indicated in candidates with poor glycemic 
control--most commonly in diabetic patients with hypoglycemia unawareness. 
Postoperative analgesia is complicated in this population due to diabetic 
gastrointestinal motility disorders (particularly gastroparesis) which are exacerbated 
by IV opioids. Reports of TAP blocks in pancreas transplant recipients are limited, 
with the first application of bilateral TAP injections of local anesthetic documented in 
2011.20 Epidural catheters are typically avoided in these patients due to risk of spinal 
hematoma and/or infection. Traditionally, pancreas transplant recipients have been 
managed with IV analgesia,21 and this was the standard at our hospital until 2013 
when bilateral TAP blocks via continuous infusion of 0.2% ropivacaine were 
instituted. In June 2016, this was replaced by a single injection of liposomal 
bupivacaine, thus eliminating the need for bilateral pain catheters. 
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 The primary objective of this study was to retrospectively compare postoperative 
pain scores and opioid use in pancreatic transplant patients who received either IV 
opioid pain management, continuous ropivacaine via TAP catheter, or liposomal 
bupivacaine. Secondary objectives included evaluation of hospital length of stay and 
return of postoperative bowel function in these 3 groups. 
 
METHODS 
 
Study design 
This was a retrospective study of all pancreas transplants performed at a single 
center from 2009 to 2017. Recipient outcomes, demographic data, laboratory values, 
and survival data were collected from the comprehensive transplant recipient registry 
maintained at our center, as well as individual written and electronic medical records. 
Anesthetic and pain interventions were extracted from intraoperative documentation 
and from post-transplant pharmacy records.  
 
Patient population 
Recipient inclusion criteria included all adult pancreas transplant recipients (18 years 
and older) that received either SPK, PAK, or PTA. Exclusion criteria included: 
presence of major surgical complications (e.g., perioperative bowel or organ injury), 
requirement for re-laparotomy, contraindication to adjuvant anesthetic intervention 
(TAP block or liposomal bupivacaine), receipt of a pancreas allograft as part of a 
multi-visceral or modified multi-visceral transplant, active daily opioid use (≥ 30 mg
oral morphine equivalent), diagnosed chronic pain syndrome, or known history of 
substance abuse within 3 months of surgery. 
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All recipients were listed for transplantation at Indiana University according to 
standard procedures and protocols as established by our own center and the United 
Network for Organ Sharing (UNOS). During the study period, in order to qualify for 
pancreas transplant listing at our institution, the potential recipient had to be insulin 
dependent with a fasting serum C-peptide level < 2 ng/ml. 
 
Procedures and immunosuppression 
Pancreas allografts were typically procured using an en-bloc technique following 
aortic flush with preservation solution and topical cooling with saline slush as 
previously described.22,23 The recipient operation was performed through a midline 
incision. The pancreas was routinely positioned with the tail toward the pelvis and 
the head and duodenum oriented superiorly in order to facilitate the enteric 
anastomosis. Systemic venous drainage was performed to the vena cava or to the 
right common iliac vein. Arterial perfusion of the allograft was routinely established 
from the right common iliac artery, although rarely if this vessel was diseased or had 
been the site for arterial anastomosis for a prior transplant, the inflow was 
established either from the aorta or the left common iliac artery. All SPK transplants 
were performed with ipsilateral placement of both the kidney and the pancreas to the 
right iliac vessels as previously described.24 Pulsatile perfusion was used routinely 
for the renal allograft portion of the SPK transplant regardless of the preservation 
solution used for organ procurement.25,26 All pancreas allografts were drained 
enterically using a stapled technique as described elsewhere.27  
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All regional anesthesia procedures at our institution were performed under 
supervision by an Acute Pain Service attending physician. All TAP catheters were 
placed with ultrasound (US) visualization. After identifying the transversus abdominis 
plane, the anesthesiologist bilaterally injected 30ml of 0.2% ropivacaine onto each 
side of the TAP space. All patients then had an elastomeric pain relief ball (ON-Q, 
Halyard Health, Roswell, Georgia, USA) attached to the TAP catheter to provide 
continuous infusion. All TAP catheters were placed at the completion of the surgery. 
In cases where liposomal bupivacaine was used, a single dose of this anesthetic 
was injected bilaterally with US visualization into each TAP space. Originally, these 
procedures were performed at the completion of the transplant operation; however, 
later study patients had TAP injections before any surgical incision. The standard of 
care changed at our institution because it was apparent that visualization of the site 
was easier before the planes had been disrupted.  
 
Patients in all 3 groups received postoperative intravenous opioids by patient-
controlled analgesia for either primary pain control (standard care group) or 
breakthrough pain (TAP block groups). At the discretion of the attending surgeon, 
and after the first flatus, patients were transitioned to an oral narcotic 
(oxycodone/acetaminophen 5 mg/325mg per os q4-6 h as needed).This was 
typically on postoperative day 2-4. 
The induction immunosuppression protocol consisted of 5 doses of rabbit 
antithymocyte globulin (rATG; 1 mg/kg/dose) and maintenance with tacrolimus 
(target trough blood concentration 6-8 ng/mL) and sirolimus (target trough blood 
concentration 3-6 ng/mL) for SPK and PAK transplants. Mycophenolate mofetil 
(MMF; 500 mg PO q12h) was added for pancreas transplant alone.28,29 Steroids 
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were exclusively used as a premedication for rATG and were discontinued following 
induction in all recipients. All recipients received routine perioperative antibiotics, 
prophylaxis against cytomegalovirus (CMV) with oral valganciclovir, and prophylaxis 
against Pneumocystis jiroveci with trimethoprim and sulfamethoxazole, unless 
contraindicated. Systemic anticoagulation was not routinely used. Nasogastric tubes 
were usually removed at the time of extubation. All patients were given 
metoclopramide (10 mg IV q6h) unless contraindicated, and methylnaltrexone (12 
mg SC q24h for the first 3 postoperative days). The metoclopramide was converted 
to oral administration prior to meals before discharge from the hospital and weaned 
whenever possible in the outpatient clinic. Urethral catheters were routinely removed 
on postoperative day 3 for all SPK transplants, and sooner, in some cases, for 
isolated pancreas transplants. 
 
Data collection and analysis 
The data obtained included pain intensity scores from postoperative day 0 to day of 
discharge, opioid usage, time to first flatus, time to first bowel movement, length of 
hospital stay, and occurrence of opioid-related side effects including nausea, 
vomiting, respiratory depression, pneumonia, and aspiration. Standard statistical 
testing was utilized for continuous and categorical variables, as indicated, including 
chi-squared analysis and analysis of variance (ANOVA). Statistical testing was 
performed on SPSS software (IBM SPSS Statistics Version 25, IBM Corporation, 
Armonk, New York, USA). This retrospective study was reviewed and approved by 
the Institutional Review Board of the Indiana University School of Medicine 
(#1011003619).  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
RESULTS 
Overall, 197 patients were included, with 46 patients (23%) receiving TAP block with 
single shot liposomal bupivacaine, 89 (45%) receiving TAP catheters with continuous 
0.2% ropivacaine, and 62 (32%) receiving no TAP block intervention (pain managed 
through IV opioids). Characteristics of transplant recipients and donors are shown in 
Table 1. The groups did not differ significantly in basic demographics or in type of 
pancreas transplant performed. The ropivacaine group was apparently under-
represented by males (47%) compared to the other two groups (65% and 61%), 
although the difference was not significant (P = .08). The groups did differ for 
pancreas donor age (P < .001), although this factor was unlikely to substantially 
impact postoperative pain control.  
 
Pain was assessed on a 0 to 10 scale by the nurse assigned to the patient (Table 2). 
Median pain scores in the post anesthesia care unit (PACU) were significantly lower 
for the standard care patients compared with both TAP groups (2.0 versus 5.6 and 
4.6, P < .001). This was also true for the average daily postoperative pain scores 
(2.6 versus 4.1 and 3.3, P < .001). Opioid usage in the PACU was highest for the 
TAP catheter group, and it was significantly lower for the standard care and 
liposomal bupivacaine groups (P = .02). Total opioid usage, however, was markedly 
lower for both TAP groups as an average daily requirement (P = .03) and for the total 
required for the first 5 days post-transplant (P = .03). The liposomal bupivacaine 
group had the lowest average daily and total opioid usage. 
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Return of intestinal function occurred more quickly for the TAP catheter and 
liposomal bupivacaine groups (P < .05), with times to first oral intake of 12 and 14 
hours, versus 26 hours for the standard care group (P < .001). Gastrointestinal 
complications (e.g., prolonged ileus) were very rare, and postoperative reinsertion of 
a nasogastric tube was rarely required. No hematomas or other injection site 
complications were observed in any patients in the TAP block groups. The 3 groups 
did not differ in length of hospital stay or 90-day graft survival. 
 
DISCUSSION 
Integrating TAP blocks into a multimodal analgesic plan for post-operative pain 
control may allow for decreased opioid use and associated side effects. Studies 
have shown the efficacy of TAP blocks in achieving adequate pain control in a 
variety of surgeries. This study is the first comparing 3 modalities of pain control in 
post-pancreas transplant patients: IV opioid pain management, continuous 
ropivacaine infusion through TAP catheter, and single-shot liposomal bupivacaine 
into the TAP space. Patients who received either TAP block intervention required 
less postoperative opioids compared to patients receiving no TAP block. The 
average daily dose of opioids was almost halved in the liposomal bupivacaine group 
and decreased by about 20% in the TAP catheter group. This is a very important 
finding as we strive to limit opioid usage at a time when opioid addiction is being 
declared a national public health emergency. Using TAP blocks following pancreas 
transplant surgery has the potential to drastically decrease opioid usage during the 
hospital stay, and this might be integrated into an enhanced recovery after surgery 
(ERAS) pathway. Campsen et al. recently described one potential post- 
nephrectomy ERAS pathway for kidney transplant donors including ketorolac and 
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pregabalin.30 We are working on ERAS pathway for pancreas transplant in our 
institution, so combining our data and current literature on ERAS pathway will be 
very helpful.  
 
Unexpectedly, patients in the standard care group reported improved pain scores in 
the PACU and POD 1-5 when compared with either TAP block intervention. 
Interestingly, multiple studies have demonstrated similar if not lower pain scores 
when comparing TAP block to IV opioid use.8,13,31 The lower pain scores for the 
standard care group in the PACU might be related to a tendency for 
anesthesiologists to administer more intraoperative opioids to patients not receiving 
nerve blocks. In addition, TAP blocks may have a lower effect on visceral pain as 
opposed to incisional somatic pain 32, and the visceral pain associated with pancreas 
transplants could potentially be greater than with many other abdominal procedures. 
The patients in the standard care group did receive significantly more postoperative 
opioids compared with the TAP block patients. The difference in median pain scores, 
although statistically significant, was rather small (2.6 for standard care group versus 
3.4 for liposomal bupivacaine during POD 1-5), and the benefits of opioid reduction 
may outweigh the small difference in pain scores. 
 
Our results support that liposomal bupivacaine provides superior analgesia 
compared to bilateral continuous TAP catheters, as the liposomal bupivacaine group 
showed significantly lower pain scores than the continuous TAP catheter group over 
postoperative days (POD) 1-5. The liposomal bupivacaine group also required less 
daily and total postoperative opioids compared to the TAP catheter group. This 
demonstrates the prolonged analgesic benefit with the single-shot liposomal 
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formulation of bupivacaine. An additional benefit of liposomal bupivacaine is the 
potentially lower risk of infection compared to implanted catheters, although 
infectious complications associated with regional anesthesia are incredibly rare 
events (on the order of 1 per 40,000-100,000 blocks).33,34 
 
Our secondary endpoints for this study involved length of hospital stay and return of 
bowel function. We hypothesized that the use of TAP blocks in these patients would 
decrease opioid use, therefore lessening the complications associated with opioids 
such as ileus and longer hospital stay. Patients receiving continuous TAP infusions 
did indeed have a faster return of bowel function, and patients receiving either TAP 
intervention had shorter time to first oral intake compared to the standard care group. 
These findings may be explained by the significantly lower amount of average daily 
and total opioids that the TAP intervention groups received over postoperative days 
1-5. There was no significant difference in length of stay, postoperative nausea and 
vomiting, or other opioid-related complications (aspiration, pneumonia, naloxone 
administration, and respiratory depression) between the 3 groups. The size and 
design of the study may have been suboptimal for detecting these endpoints, 
however, as there were only 2 aspiration events, 1 documented pneumonia, and 1 
naloxone administration for all of the patients in the study.  
 
A potential strength of this study is the standardization of the transplant team (all 
procedures were performed by a team of 2 transplant surgeons that performed the 
majority of transplants together), operative technique, immunosuppression strategy 
and postoperative management. Limitations include lack of study blinding and 
randomization, as these were not possible in a retrospective study. We were also 
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unable to control for other factors such as changes over time to institutional 
standards, postoperative nursing care, and/or data entry.  
 
One anesthesia protocol factor that changed during this study was the timing of 
liposomal bupivacaine injection (originally performed at the completion of the 
transplant but later performed prior to incision). Later TAP blocks would potentially 
be more successful due to improved visualization afforded by preoperative 
injections. The exact transition date from post-surgery to preoperative TAP blocks 
was not noted; therefore, we were unable to compare these procedural differences.  
 
Another factor that may have changed over time was the widespread institutional 
drive to initiate oral diets sooner due to beliefs regarding opioid minimization. This 
might have impacted the study outcome on time to first oral diet, as attending 
physicians might be increasingly skewed over time to allow earlier oral intake. The 
effect should be minimal in our study since there was a consistent attending surgeon 
using an objective criterion (time to first flatus) before allowing an oral diet. 
 
Since return of bowel function was a study endpoint, our protocol to reduce opioid-
induced bowel dysfunction should be noted as it may have impacted factors such as 
time to first flatus, time to first oral intake, and time to first stool output. The protocol 
includes removal of nasogastric tubes at the completion of the procedure with early 
introduction of oral intake, liberal use of intravenous metoclopramide as a prokinetic 
agent, and subcutaneous methylnaltrexone (peripheral -opioid antagonist). Patients 
in all groups received the same care; therefore, this should not have impacted the 
comparison of groups. 
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The significantly lower 90-day readmission rate for the TAP catheter group was an 
unexpected finding in this study. This finding is most likely an era-related 
phenomenon reflecting practice patterns and an institutional drive to lower hospital 
readmissions. It is unlikely that a specific perioperative analgesic protocol alone 
could have such an impact on the need for hospital readmission at 3 months 
postoperative. No other overt factors in the study groups were identified to account 
for the differences in readmission rates. 
 
In conclusion, TAP block techniques may be opioid-sparing in the postoperative 
period following pancreatic transplant. A single dose of liposomal bupivacaine by 
TAP block provided better analgesia in this study compared with ropivacaine by 
implanted TAP catheters. 
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TABLES 
 
 
Table 1. Analysis of pancreas transplant recipients and donors with stratification by anesthesia intervention 
 
 
  
Total Anesthesia intervention 
  
Standard care TAP catheters Liposomal bupivacaine P value 
Number of patients 197 62 (32%) 89 (45%) 46 (23%) 
 
Transplant recipients 
   Age (years) 44 (18-66) 46 (28-65) 43 (18-63) 44 (27-66) .23 
   Gender: Male 56% 65% 47% 61% .08 
   Race: White 90% 95% 88% 87% .18 
   Body mass index (kg/m2) 25.7 (17.6-39.2) 25.2 (17.6-39.2) 25.7 (18.8-38.2) 25.8 (18.6-32.4) .30 
Transplant type 
   Pancreas and kidney 115 (58%) 60% 54% 65% .24 
   Pancreas after previous kidney 24 (12%) 18% 10% 9% 
   Pancreas transplant alone 58 (29%) 22% 36% 26% 
Pancreas donors 
   Age (years) 24 (7-49) 26 (19-49) 22 (7-38) 25 (11-48) .001 
   Gender: Male 61% 61% 61% 62% 1.00 
   Race: White 80% 85% 75% 85% .05 
   Body mass index (kg/m2) 23.6 (13.0-39.5) 24.0 (13.8-39.5) 23.5 (13.0-33.9) 23.4 (16.8-39.5) .75 
 
Cause of donor death 
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   Stroke 9% 12% 8% 5% .38 
   Trauma 59% 54% 65% 53% 
 
   Anoxic brain injury 32% 34% 27% 42% 
 
 
 
    Transplant procedure  
 
   
   Length of surgery (minutes) 280 (105-537) 267 (124-475) 275 (105-409) 306 (120-537) .09 
   Average blood loss (mL) 250 (0-1500) 300 (50-1500) 250 (20-1000) 250 (0-1000) .26 
 
 
    
 
mL = milliliters; TAP = transversus abdominis plane 
Continuous variables are reported as median with range 
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Table 2. Summary of daily pain scores and opioid use in pancreas transplant recipients by anesthetic intervention 
 
  
Anesthesia intervention 
  Overall Standard care TAP catheters Liposomal bupivacaine P value 
Number of patients 197 62 (32%) 89 (45%) 46 (23%) 
Pain scores (0-10 scale) 
   PACU < .001 
     Mean (SE) 3.9 (0.21) 2.7 (0.33) 4.7 (0.31) 4.1 (0.45) 
     Median (range) 3.8 (0-10) 2.0 (0-10) 5.6 (0-10) 4.6 (0-10) 
   Postop day 0 .81 
     Mean (SE) 3.8 (0.17) 3.6 (0.31) 3.9 (0.26) 3.8 (0.32) 
     Median (range) 4.0 (0-10) 3.1 (0-10) 4.1 (0-10) 4.2 (0-8) 
   Postop days 1-5 (average daily score) < .001 
     Mean (SE) 3.5 (0.12) 2.9 (0.19) 3.9 (0.17) 3.4 (0.23) 
     Median (range) 3.4 (0-7) 2.6 (0-7) 4.1 (0-7) 3.4 (0-7) 
Opioid use (calculated mg morphine 
equivalent) 
   PACU .02 
     Mean (SE) 13 (1.4) 9 (2.0) 17 (2.4) 11 (2.0) 
     Median (range) 8 (0-124) 0 (0-80) 12 (0-124) 8 (0-60) 
   Postop day 0 .29 
     Mean (SE) 57 (9.0) 70 (19.0) 61 (14.7) 32 (5.2) 
     Median (range) 24 (0-936) 26 (0-936) 28 (0-936) 24 (0-140) 
   Postop days 1-5 (daily requirement) .03 
     Mean (SE) 91 (7.1) 113 (18.6) 90 (7.5) 63 (6.8) 
     Median (range) 62 (5-919) 78 (13-919) 68 (5-383) 50 (8-236) 
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mg 
= 
milli
gra
ms; 
PA
CU 
= 
post 
ane
sthe
sia care unit; postop = postoperative; SE = standard error; TAP = transversus abdominis plane 
 
  Postop days 1-5 (total) .03 
     Mean (SE) 682 (53.9) 846 (142.4) 680 (58.0) 465 (49.8) 
     Median (range) 465 (36-7354) 529 (102-7354) 484 (36-3064) 349 (65-1655) 
Clinical outcomes (median, range) 
   Time to first flatus (hours) 53 (2-145) 55 (2-145) 50 (9-100) 53 (3-130) .22 
   Time to first stool output (hours) 65 (1-170) 71 (3-170) 60 (12-160) 68 (1-125) .04 
   Time to first oral intake (hours) 15 (1-126) 26 (4-96) 12 (1-62) 14 (1-126) < .001 
   Length of hospital stay (days) 7 (3-117) 7 (3-15) 7 (4-117) 6 (5-30) .44 
   90-day graft survival 99% 98% 100% 100% .34 
   90-day readmission 47% 60% 30% 61% < .001 
